Indivi develops digital biomarkers that turn smartphones and everyday devices into measurement tools for neuroscience drug development. The CHF 15 million capital increase will fund, from 2026, a proof-of-concept trial in Alzheimer's disease.
- Announced on
- Round
- Undisclosed round
- Amount
- CHF 15 M
- Location
- Basel, canton of Basel-Stadt
- Sector
- Health & medtech
Investors
- Ava Investors lead
- Leclercq American Capital
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic